Knight to Present at Stifel GMP’s The Future of Healthcare Conference

·2 min read

MONTREAL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be held virtually. A live webcast of the event will be available at the following link: Event. A copy of the presentation will be available at www.gud-knight.com.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Investor Contact:

Knight Therapeutics Inc.

Samira Sakhia

Arvind Utchanah

President & Chief Executive Officer

Chief Financial Officer

T: 514.484.4483

T. 514.484.4483

F: 514.481.4116

F. 514.481.4116

Email: info@knighttx.com

Email: info@knighttx.com

Website: www.gud-knight.com

Website: www.gud-knight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting